Model Medicines

Transforming Pandemic Preparedness: AI-Driven Predictive Tools + Next-Generation Broad-Spectrum Antivirals ?? A New Era of Pandemic Response - Nature Paper: "Artificial intelligence for modelling infectious disease epidemics" A new groundbreaking article in Nature highlights how artificial intelligence (AI)—from deep generative models to graph neural networks—is radically improving our ability to predict and manage infectious diseases. Nature Paper linked here: https://lnkd.in/eZzN3Sq8 Why AI-driven Epidemiology Matters: ??? Speed: AI rapidly processes vast amounts of data—like genomic sequences, travel patterns, and social media trends—to instantly track outbreaks. ?? Precision: Real-time, location-specific predictions help target interventions precisely. ?? Continuous Improvement: AI systems continuously learn and adapt, offering more accurate predictions over time. ?? Reliable Forecasts: Enhanced data integration leads to fewer errors and more trustworthy decision-making. Congratulations to all involved in the paper: Moritz U G Kraemer, PhD - https://lnkd.in/gUuxk_Qj Joseph L.-H. Tsui Serina Chang Spyros Lytras? Mark Khurana Samantha Vanderslott Sumali Bajaj Neil Scheidwasser Jacob Liam Curran-Sebastian Elizaveta Semenova Mengyan Zhang Juliette (Ettie) Unwin Oliver Watson Cathal Mills Abhishek Dasgupta Luca Ferretti Samuel Scarpino Etien Luc Koua, PhD Oliver Morgan Houriiyah Tegally Ulrich Paquet Loukas Moutsianas Christophe Fraser Neil Ferguson Eric Topol, MD David A. Duchêne Tanja Stadler Prof. Patricia Kingori Michael P. francesca dominici Nigel Shadbolt Marc A. Suchard Oliver Ratmann Seth Flaxman Edward C. Holmes Manuel Gomez Rodriguez Bernhard Sch?lkopf Christl Donnelly Oliver Pybus Simon Cauchemez Samir Bhatt - https://lnkd.in/gHhZCnE5

2025: The Inflection Year?- Pushing the Industry Forward with AI and Quantum Computing The past few weeks have marked a turning point for our industry. Insilico Medicine and Model Medicines have released groundbreaking papers that highlight how Quantum Computing and Generative AI are redefining what’s possible in drug discovery. 2025 is the inflection year. The year where AI-driven generative models and quantum-enhanced methods are not just theoretical—they are delivering results. This isn’t just about accelerating discovery; it’s about fundamentally reshaping how we find new medicines. Quantum (Insilico) - https://lnkd.in/gyb4hEVj Generative (Model) - https://lnkd.in/gK8DK_jA The numbers speak for themselves (see images). ?? What this means for drug discovery: - A combined AI + Quantum approach could generate trillions, screen billions, and identify nearly 3x more viable drug candidates than either method alone. - Hit rates could increase nearly 4x over quantum approaches alone, drastically improving efficiency. - Greater molecular diversity and novelty, as shown in Tanimoto scores, means we are expanding beyond known chemical space faster than ever before. This is the industry moving forward. AI-driven discovery and quantum computing are no longer just ideas—they are the foundation of modern drug discovery. We admire Alex Zhavoronkov’s leadership in quantum-enhanced drug discovery, but this is bigger than just our companies. This is about pushing the industry forward. Both Inscilico and Model Medicines were recently named "Ten Companies to Watch in AI Drug Discovery" by Alex Philippidis at Genetic Engineering & Biotechnology News Congratulations to the authors of "Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors" - Mohammad Ghazi Vakili, Christoph Gorgulla, Jamie Snider, AkshatKumar Nigam, Dmitry Bezrukov, Daniel Varoli-Vasilevskiy, Alex Aliper, Daniil Polykovskiy, Krishna Padmanabha Das, Huel “Trey” Cox III, Anna Lyakisheva, Ardalan Hosseini, Zhong Yao, Lela Bitar, Danielle Tahoulas, Dora ?erina, Eugene Radchenko, Xiao Ding, Jinxin Liu, Fanye Meng, Feng Ren, Yudong Cao, Igor Stagljar, Alán Aspuru-Guzik, and Alex Zhavoronkov. GALILEO Generatively Expands Chemical Space and Achieves One-Shot Identification of a Library of Novel, Specific, Next Generation Broad-Spectrum Antiviral Compounds at High Hit Rates - Tyler Umansky, Virgil Woods, Sean Russell, David Garvey, Davey Smith, MD, MAS, FACP, FIDSA, Daniel Haders II, Ph.D. Read the full article here: https://lnkd.in/gYsxcdmZ

?? The AI Drug Discovery Industry is at an Inflection Point ?? Last week, STAT News Brittany Trang released a must-read investigative piece exposing exaggerated AI claims in drug discovery. The next day Fierce Biotech's, Conor Hale featured Insilico Medicine (Alex Zhavoronkov) detailing real AI-driven drug development progress. It’s no coincidence these reports came out in the same week. When an industry moves from hype to maturity, companies are revealed for what they truly are—those that lead with science and transparency, and those that rely on marketing spin. https://lnkd.in/gHHGExEi ?? What the STAT News Report Exposed - https://lnkd.in/gcsBPEmy Many companies claim to be designing drugs from scratch with AI, however, the reality is that they are tweaking existing molecules, not generating truly novel compounds. As Trang notes: “AI pharma and biotech companies’ breathless claims can potentially mislead anyone not intimately familiar with the details of drug development or machine learning.” This has fueled skepticism within the biotech community, especially in forums like Reddit/biotech (https://lnkd.in/g7hNec2Q). ?? What the Fierce Biotech Report Highlighted - https://lnkd.in/eSyF4Kty In contrast, Fierce showcased AI’s potential when applied correctly, underscoring how companies using robust methodologies are leading the industry forward, not just making noise to attract investment. ?? The Key Takeaway: AIDD companies must be transparent in their models and science. ?? At Model Medicines, we prove everything. That’s why we developed the AIDD Code—six key criteria for success in AI-powered drug discovery: 1?? New Biology & Target Discovery – Identifying novel biological pathways 2?? New Chemical Entities – Truly new molecules, not minor modifications 3?? Zero-Shot Hit Rates >30% at <20μM – AI predictions that work in real-world testing 4?? Tanimoto Scores <0.5 – Ensuring genuine novelty, not slight tweaks 5?? A Diverse Pipeline – Expanding across multiple disease areas 6?? Preclinical Proof-of-Concept – Validated efficacy in gold-standard animal models ?? Read more - AI Hit Rates and Novelty: Model Medicines AI Drug Discovery - https://lnkd.in/g3HsfYGN The STAT News report has put the spotlight on AI-driven biotech, forcing the industry to choose - We choose transparency, real hit rates, mathematical novelty, and tangible progress. AI drug discovery doesn’t need hype. It needs leaders who prove their success through science, transparency, and real-world impact. ?? Join the conversation: Who leads with transparency in AI drug discovery?

With LEAP underway in Riyadh, Model Medicines' CEO, Daniel Haders II, Ph.D., delivered a recent keynote in Saudi Arabia - When Digitalization Fails: The Future of AI Drug Discovery What happens when billions of dollars are invested in AI for drug discovery, yet not a single AI-discovered medicine has been approved? Model Medicines CEO, Daniel Haders II, Ph.D. tackled this question head-on in his keynote at CPHI Middle East, the region's premier pharmaceutical conference, presented under the patronage of the Ministry of Health Saudi Arabia ?? Watch the full video here https://lnkd.in/eKZiNEk7 Key Takeaways from the Keynote: ?? AI drug discovery is seven decades in the making, but why hasn’t it delivered? ?? The pharmaceutical industry has over-focused on digital solutions without defining the right problems. ?? MDL-001—our AI-discovered, broad-spectrum antiviral—is proving that AI can work when paired with novel biology insights and real-world validation. The future of AI in drug discovery isn’t just about digital solutions—it’s about defining the right problems and integrating human expertise. A special thanks to those who made the event possible. Ministry of Health Saudi Arabia Saudi Vision 2030 Events Investment Fund Tahaluf ?????? ?????? ?????? ????? | Saudi NIH SFDA - ???? ?????? ??????? Lifera SPIMACO AJA Pharma NEOM Julphar Sudair Pharmaceutical Company Iraqi Pharmaceutical Industry Co. Tabuk Pharmaceuticals Manufacturing Company EVA pharma

Model Medicines recognized as an AI-Driven Leader in Drug Discovery by both Fierce Biotech and Genetic Engineering & Biotechnology News (GEN) for our AI-powered breakthroughs in antiviral drug discovery. ?? Darren Incorvaia at Fierce Biotech spotlighted our lead candidate, MDL-001, a first-in-class broad-spectrum antiviral that targets a previously unexploited site—Thumb-1 of RNA-dependent RNA polymerase (RdRp). Unlike conventional antivirals, MDL-001 demonstrates: ? Superior preclinical efficacy—2.9 Log10 viral load reduction, exceeding Paxlovid’s active ingredient. ? Broad-spectrum antiviral activity—potent against SARS-CoV-2, norovirus, influenza, and hepatitis C. ? Oral bioavailability—designed for once-daily outpatient use, making it an ideal candidate for pandemic preparedness. ?? Fierce Biotech also highlighted our new hub-and-spoke model—the VIROMME? Program (www.viromme.com), a dedicated AI-driven antiviral therapeutics initiative, allowing us to: ?? Scale AI-powered drug discovery efficiently. ?? Accelerate commercialization through partnerships, licensing, and IPOs. ?? Expand into new AI-driven therapeutic areas, including oncology. ?? Alex Philippidis from GEN named Model Medicines as one of the “Ten Companies to Watch in AI Drug Discovery”, alongside industry leaders like Recursion Pharmaceuticals and Schr?dinger. GEN specifically calls out that Model Medicines "has one of the largest disclosed?pipelines?of any AI-based drug discovery company." At Model Medicines, we are redefining what’s possible in AI-driven drug discovery. The future of medicine is AI-powered, and we are leading the way. ?? Read more about our breakthroughs in Fierce Biotech & GEN https://lnkd.in/gfVShNfj https://lnkd.in/ene2qWTy #AIDD #DrugDiscovery Daniel Haders II, Ph.D. Sean Russell?Tyler Umansky?Virgil Woods?Patrick ONeill?Lani O.?Tushar Menon, PhD?JD?Davey Smith, MD, MAS, FACP, FIDSA?Karl Karlsson Irving Investors?Christopher Chism?Jeremy Abelson?Andrew Kalmar?ParticleX?Jeffrey Friedman?Clayton E. Hartman?Philip Treick?Kevin Whalen?Cameron Akers?Greg Young?Wayne Schellhammer?Doug Vander Weide, CFP???Jennifer Schmitke, PhD?Sam Howard Launa Aspeslet Delilah Panio Greg Goldner Brendan Hussey, Ph.D Fan Zhang, PhD David Smolensky Megan Wilson Launa Aspeslet 8VC James A Weber

Model Medicines Unveils Generative AI, Multi-Modal Therapeutic Pipeline Breakthrough, Demonstrating End-To-End Drug Discovery Capabilities Model Medicines has achieved a groundbreaking milestone, as detailed in our latest preprint, showcasing end-to-end drug discovery capabilities: ? Novel target discovery: Identification of the conserved RdRp Thumb-1 as a broad-spectrum antiviral target. ? Mechanism of Action (MoA) insights: Transforming the antiviral therapeutic paradigm. ? Novel chemical discovery: Generating a library of 12 new chemical entities (NCEs) with unprecedented specificity. ? Preclinical Proof-of-Concept (PoC): Delivering first-in-class therapeutics at 100% hit rates, faster and more efficiently than ever before. With this, Model Medicines has demonstrated end-to-end drug discovery capabilities—novel target and Mechanism of Action(MoA) discovery, novel chemical discovery, and preclinical Proof-of-Concept(PoC)--against a first-in-class Target Product Profile(TPP) at unprecedented hit rates (100%) leveraging Generative-AI, Multi-Modal Models and a 0/1-Shot Discovery Approach. ?? This achievement, comes via our new preprint "GALILEO Generatively Expands Chemical Space and Achieves One-Shot Identification of a Library of Novel, Specific, Next-Generation Broad-Spectrum Antiviral Compounds at High Hit Rates" - Leveraging our proprietary platform, we explored a chemical space of 50 trillion compounds, achieving specificity improvements up to 15,000-fold over our previous lead candidate compound. ?? Check out the latest preprint here: https://lnkd.in/gK8DK_jA Full List of Authors: Tyler Umansky Virgil Woods Sean Russell David Garvey Davey Smith, MD, MAS, FACP, FIDSA Daniel Haders II, Ph.D. Want to learn more? This research builds on two prior preprint announcements: 1?? Discovery of RdRp Thumb-1 as a Novel Broad-Spectrum Antiviral Family of Targets - https://lnkd.in/gRHKPTvv 2?? MDL-001: An Oral, Safe and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases - https://lnkd.in/g-t7szAz Patrick ONeill?Lani O.?Tushar Menon, PhD?JD?Karl Karlsson Launa Aspeslet James A Weber #Biotech #DrugDiscovery #GlobalHealth #AntiviralTherapeutics #PandemicPreparedness #AIDD

Model Medicines, Icahn School of Medicine at Mount Sinai, and UC San Diego Health Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral. We’re thrilled to announce the release of our groundbreaking preprint, “MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases”. This pivotal research highlights the potential of MDL-001, a first-in-class, orally administered, broad-spectrum antiviral therapy designed to combat urgent global health threats, including SARS-CoV-2, influenza, norovirus, and hepatitis C. https://lnkd.in/eKXGHjpY Key Highlights: ? Demonstrates robust activity against 4 viral families, 7 distinct viruses, and 13 viral variants and strains. ? Superior preclinical efficacy compared to existing antivirals like remdesivir and Paxlovid. ? Once-daily oral dosing with a favorable safety profile validated in two Phase 1 clinical trials involving ~100 healthy subjects. MDL-001 represents a leap forward in pandemic preparedness, meeting the stringent Target Product Profile (TPP) set by the National Institute of Allergy and Infectious Diseases (NIAID). We’re proud to collaborate with leading virologists and infectious disease experts, including: ?? Adolfo García-Sastre, PhD (Icahn School of Medicine) ?? Kris White (Icahn School of Medicine) ?? Davey Smith, MD, MAS, FACP, FIDSA (UC San Diego) Full List of Authors: Virgil Woods Tyler Umansky Sean Russell Briana McGovern Romel Rosales Ramirez, Msc PhD M Luis Rodriguez Harm van Bakel Emilia Mia Sordillo Viviana Simon Adolfo?García-Sastre Kris White Davey Smith, MD, MAS, FACP, FIDSA Daniel Haders II, Ph.D. Icahn School of Medicine at Mount Sinai Mount Sinai Health System Mount Sinai Innovation Partners CEIRR Network (admin) National Institute of Allergy and Infectious Diseases (NIAID) Patrick ONeill?Lani O.?Tushar Menon, PhD?JD?Karl Karlsson Launa Aspeslet James A Weber #Biotech #DrugDiscovery #GlobalHealth #AntiviralTherapeutics #PandemicPreparedness #AIDD

We’re thrilled to share that our very own Daniel Haders II, Ph.D. will be speaking on the first panel of an upcoming event centered on the future of science, AI, and deep tech! It’s exciting to see these inaugural sessions focused on the intersection of biotechnology, hard tech, and AI, underscoring how rapidly advancing computational approaches are reshaping R&D and fueling groundbreaking discoveries. At Model Medicines, we’re harnessing AI to accelerate drug discovery and deliver life-changing treatments to patients faster. It’s thrilling to see events like TechCon SoCal recognize the critical impact of hard tech, cutting-edge science, and artificial intelligence in advancing next-generation healthcare solutions. Daniel will be speaking on the first panel at TechCon SoCal 2025, taking place January 17–18 in San Diego, California. This session, “Pioneering Innovations in Biotechnology: From Concept to Commercialization,” explores how AI and deep tech are shaping drug discovery and broader biopharma R&D, and it promises to be an essential conversation about AI readiness rather than hype. The full panel includes: ? Carl Schoellhammer, Associate Partner, Decibio Consulting ? Remo Moomiaie-Qajar M.D. Moomiaie-Ojar, CEO, Cytonus Therapeutics ? Chris Garabedian, Chairman & CEO, Xontogeny ? Chris Jacob, Founder, Gateway Genomics Recent insights across the industry point to a pivotal shift. Key themes from #JPM 2025 include: ? Large Biopharma is betting big on AI, investing heavily in platforms and top-down initiatives to shorten R&D timelines. ? Smaller Biotech is steadily utilizing AI-driven technologies with a measured, ROI-focused approach. ? High-Quality Data is emerging as the critical fuel for AI’s potential, highlighted by collaborations like NVIDIA Healthcare with IQVIA, Illumina, and Mayo Clinic. ? Regulatory Momentum is building, with the FDA offering draft guidance that underscores AI’s importance in the future of drug development.

Model Medicines is proud to participate in CPHI Middle East, the region's premier pharmaceutical conference, which is being presented under the patronage of the Ministry of Health Saudi Arabia. As Saudi Arabia emerges as a global biotechnology leader within the pharmaceutical industry, this prestigious event brings together industry pioneers to discuss innovation, digital transformation, and the future of drug discovery. CPHI Middle East - 10-12 Dec 2024 I Riyadh, Saudi Arabia https://lnkd.in/g67VB2fW Representing Model Medicines will be CEO and Founder Daniel Haders II, Ph.D. and Head of Partnerships Patrick ONeill On December 12th, Daniel Haders II, Ph.D. will deliver a Keynote Presentation - "When Digitalisation Fails: Facing Digital Shortcomings" at the Future Stage. Daniel will address the critical challenges and opportunities in pharmaceutical digitalization in his keynote. Drawing from extensive industry experience, Dr. Haders will explore common pitfalls in digital transformation initiatives, strategic approaches to overcome implementation challenges, case studies, and practical solutions outlook for digital innovation in pharma. In addition to the keynote on Dec 12th, Daniel Haders II, Ph.D. will join a Panel Discussion -"Exploring AI Potential in Pharma for Drug Discovery and Development" also at the Future Stage. Moderated by Dean Calhoun, CIH, President/CEO of Affygility Solutions, alongside Thrasyvoulos Karydis, Co-Founder and CTO of DeepCure, and Majd Abdulghani, PhD, genomics lead at Lean Business Services and Saudi Arabia's first Rhodes Scholar. The panel will delve into the latest developments in AI-driven drug discovery and the impact of artificial intelligence on development timelinesFuture possibilities for AI in pharmaceutical innovation collaborative opportunities in the Middle East's growing biotech sector. About CPHI Middle East 2024 CPHI Middle East 2024 will bring together over 400 exhibitors and 30,000 visitors from 100+ countries, focusing on pharmaceutical innovations, networking, and market opportunities in the Middle East. With more than 150 speakers and a backdrop of Saudi Arabia’s rapidly growing pharmaceutical market (projected to reach USD 12.1 billion), this gathering represents a significant opportunity for industry leaders to connect, learn, and drive forward pharmaceutical advancements in the region. A special thanks to those making this event possible. Ministry of Health Saudi Arabia Saudi Vision 2030 Events Investment Fund Tahaluf ?????? ?????? ?????? ????? | Saudi NIH SFDA - ???? ?????? ??????? Lifera SPIMACO AJA Pharma NEOM Julphar Sudair Pharmaceutical Company Iraqi Pharmaceutical Industry Co. Tabuk Pharmaceuticals Manufacturing Company EVA pharma

Join us tomorrow at the Future Stage! Model Medicines is excited to participate in CPHI Middle East, the region's premier pharmaceutical conference, which is being presented under the patronage of the Ministry of Health Saudi Arabia. As Saudi Arabia emerges as a global biotechnology leader within the pharmaceutical industry, this prestigious event brings together industry pioneers to discuss innovation, digital transformation, and the future of drug discovery. CPHI Middle East - 10-12 Dec 2024 I Riyadh, Saudi Arabia https://lnkd.in/g67VB2fW Representing Model Medicines will be CEO and Founder Daniel Haders II, Ph.D. and Head of Partnerships Patrick ONeill On December 12th, Daniel Haders II, Ph.D. will deliver a Keynote Presentation - "When Digitalisation Fails: Facing Digital Shortcomings" at the Future Stage. Daniel will address the critical challenges and opportunities in pharmaceutical digitalization in his keynote. Drawing from extensive industry experience, Dr. Haders will explore common pitfalls in digital transformation initiatives, strategic approaches to overcome implementation challenges, case studies, and practical solutions outlook for digital innovation in pharma. In addition to the keynote on Dec 12th, Daniel Haders II, Ph.D. will join a Panel Discussion -"Exploring AI Potential in Pharma for Drug Discovery and Development" also at the Future Stage. Moderated by Dean Calhoun, CIH, President/CEO of Affygility Solutions, alongside Thrasyvoulos Karydis, Co-Founder and CTO of DeepCure, and Majd Abdulghani, PhD, genomics lead at Lean Business Services and Saudi Arabia's first Rhodes Scholar. The panel will delve into the latest developments in AI-driven drug discovery and the impact of artificial intelligence on development timelinesFuture possibilities for AI in pharmaceutical innovation collaborative opportunities in the Middle East's growing biotech sector. About CPHI Middle East 2024 CPHI Middle East 2024 will bring together over 400 exhibitors and 30,000 visitors from 100+ countries, focusing on pharmaceutical innovations, networking, and market opportunities in the Middle East. With more than 150 speakers and a backdrop of Saudi Arabia’s rapidly growing pharmaceutical market (projected to reach USD 12.1 billion), this gathering represents a significant opportunity for industry leaders to connect, learn, and drive forward pharmaceutical advancements in the region. A special thanks to those making this event possible. Ministry of Health Saudi Arabia Saudi Vision 2030 Events Investment Fund Tahaluf ?????? ?????? ?????? ????? | Saudi NIH SFDA - ???? ?????? ??????? Lifera SPIMACO AJA Pharma NEOM Julphar Sudair Pharmaceutical Company Iraqi Pharmaceutical Industry Co. Tabuk Pharmaceuticals Manufacturing Company EVA pharma